A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

October 31, 2012

Conditions
LeukemiaAmyloidosis
Interventions
DRUG

Lenalidomide

"Lenalidomide is a a derivative of thalidomide.~Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."

DRUG

Melphalan

"Melphalan is a phenylalanine derivative of mechlorethamine.~Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"

DRUG

Dexamethasone

"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.~Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"

Trial Locations (1)

94305

Stanford University Cancer Institute, Stanford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Stanford University

OTHER

NCT00890552 - A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis | Biotech Hunter | Biotech Hunter